Results 81 to 90 of about 5,708,022 (299)

Tuning Mechanoreceptor Signaling Enhances the Adjuvant Effect of Biomaterial Vaccines

open access: yesAdvanced Functional Materials, EarlyView.
Matrix stiffness serves as an independent immunological signal in biomaterial vaccines. Stiffer microporous hydrogel vaccines enhance dendritic cell maturation and migration to draining lymph nodes, promote T follicular helper cell expansion through Yap/Taz signaling, and increase antigen‐specific antibody production.
Lily Shang   +13 more
wiley   +1 more source

Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions

open access: yesVaccines, 2021
The development of cancer vaccines has been intensively pursued over the past 50 years with modest success. However, recent advancements in the fields of genetics, molecular biology, biochemistry, and immunology have renewed interest in these ...
Ban Qi Tay   +9 more
semanticscholar   +1 more source

Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden

open access: yesAdvanced Healthcare Materials, EarlyView.
Nanoemulsion delivery of a TLR7 agonist enhances safety and promotes colocalization with Leishmania‐infected macrophages in skin lesions, enabling a ∼2‐log reduction in parasite burden. However, tissue‐level constraints and TLR‐driven regulatory feedback generate a mixed immune response that limits complete parasite clearance.
Carmen Palomino‐Cano   +11 more
wiley   +1 more source

HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques

open access: yesNature Communications
Simian or Human immunodeficiency virus (SIV or HIV) vaccines based on V1-deleted envelope virus-like particles, delivered by the DNA/ALVAC platforms, followed by the ΔV1gp120 boost formulated in Alum, protect 50% and 80% of macaques from mucosal ...
Massimiliano Bissa   +24 more
doaj   +1 more source

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization

open access: yesCell Reports, 2019
Summary: Broadly HIV-1 neutralizing VRC01 class antibodies target the CD4-binding site of Env. They are derived from VH1-2∗02 antibody heavy chains paired with rare light chains expressing 5-amino acid-long CDRL3s.
K. Rachael Parks   +18 more
doaj   +1 more source

Advances in Immunotherapy and Vaccine for Prostate Cancer

open access: yesAnnals of Urologic Oncology, 2023
Prostate cancer is one of the most common malignant tumors of the urinary system. The incidence of prostate cancer is high in the elderly male patients, which seriously threatens the life and health. In recent years, immunotherapy to activate anti-cancer
Wei Zhou, Yikai Zhang
doaj   +1 more source

Cancer vaccines: Target antigens, vaccine platforms and preclinical models.

open access: yesMolecular Aspects of Medicine
This review provides a comprehensive overview of the evolving landscape of cancer vaccines, highlighting their potential to revolutionize tumor prevention. Building on the success of vaccines against virus-related cancers, such as HPV- and HBV-associated
F. Ruzzi   +9 more
semanticscholar   +1 more source

The current clinical landscape of personalized cancer vaccines.

open access: yesCancer Treatment Reviews, 2022
Due to the intrinsic genetic instability of tumor cells, aberrant and novel tumor antigens can be expressed and serve as potential targets for cancer immunotherapy. This intrinsic feature can be exploited by cancer immunotherapy, particularly with cancer
Hajer Fritah   +3 more
semanticscholar   +1 more source

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

open access: yesAdvanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa   +3 more
wiley   +1 more source

Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies

open access: yesTheranostics, 2022
Rationale: Messenger RNA (mRNA) vaccine outperforms other kinds of cancer immunotherapy due to its high response rates, easy preparation, and wide applicability, which is considered as one of the most promising forms of next-generation cancer therapies ...
Hongjian Li   +8 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy